Oncology Conference update

ESMO Virtual Plenary: Final OS results from the phase III TROPION-Breast01 trial

How will the latest Dato-DXd data impact treatment strategies for HR+/HER2− mBC?

Prof. François-Clément Bidard

Prof. François-Clément Bidard
Dr Barbara Pistilli

Dr Barbara Pistilli
Publication Date

Feb 2025

download

Prof. François-Clément Bidard and Dr Barbara Pistilli share expert insights on the latest TROPION-Breast01 update, presenting the final OS results from the ESMO Virtual Plenary 2025.

 

This study evaluates datopotamab deruxtecan (Dato-DXd) versus chemotherapy in previously treated, inoperable or metastatic HR+/HER2– breast cancer. 

 

In this video, the experts explore: 

  • Mechanism of action of Dato-DXd 
  • TROPION-Breast01 PFS results and safety outcomes 
  • Final overall survival results and their clinical implications 
  • The future outlook for Dato-DXd 

 

Clinical takeaways

 

  • TROPION-Breast01 final OS results did not reach statistical significance; however, subsequent ADC treatment may have influenced survival outcomes
  • The dual primary endpoint of PFS demonstrates a statistically significant and clinically meaningful improvement with Dato-DXd compared with chemotherapy
  • Secondary efficacy and PRO endpoints continued to show a benefit for Dato-DXd in this final analysis

 

Download the Virtual Plenary slides from ESMO's OncologyPro website: www.oncologypro.esmo.org

  • Recognise the efficacy and safety profiles of TROP2-directed ADCs for patients with advanced or metastatic HR+/HER2- BC, and their place in the treatment landscape  
  • Implement optimization of treatment selection, and make the appropriate sequencing decisions  
  • Be able to monitor and manage adverse events associated with ADC therapy 

François-Clément Bidard, MD PhD, is a Professor of Medical Oncology in Paris and Saint-Cloud, France. His clinical work is dedicated to breast cancer care, whereas his translational and clinical research focuses on all forms of liquid biopsy and new therapies to move ahead of cancer resistance.

Prof. François-Clément Bidard has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Prof. Bidart discloses financial support/sponsorship from AstraZeneca, Daiichi-Sankyo, Caris, Exact Sciences, General Electrics Healthcare, GSK, Inatherys, Lilly, Merck KGaA, Menarini Silicon Biosystems, Menarini/Stemline, Novartis, Pfizer, Prolynx, Rain Oncology, Roche, SAGA Diagnostics, Seagen, Sanofi

Programme summary
  • clock Duration 5 MIN
  • clock Language(s) flag
Watch the video now
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from AstraZeneca
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology, AstraZeneca and Thermo Fisher Scientific.

Meet the experts Independent IME approved

Other programmes of interest

podcast Podcast
Oncology 
HR+/HER2- metastatic breast cancer: Best practices in molecular testing and targeted therapy

Optimising precision medicine for improved patient outcomes

Experts
Dr Roberto Salgado, Assoc. Clinical Professor Rena Callahan
Endorsed by
ICAN international cancer advocacy network ISLB Exon20group
Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Mar 2025
PRECISION ONCOLOGY CONNECT BREAST CANCER CONNECT Non-accredited Independent Medical Education
Educational programme supported by an Independent Educational Grant from Thermo Fisher Scientific.
conference-update Conference update
Oncology 
Current and future treatment strategies for patients with ER+/HER2- early breast cancer

A closer look at the evolving treatment landscape

Experts
Prof. Michael Gnant, Prof. Giuseppe Curigliano
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Mar 2025
COR2ED
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
video Video
Oncology 
LEAP-012 publication snapshot

Expert insights on multimodal treatment for intermediate hepatocellular carcinoma (HCC)

Experts
Prof. Arndt Vogel
Endorsed by
DiCE Global Liver Institute Blue Faery plus
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Mar 2025
HCC CONNECT GI CONNECT Non-accredited Independent Medical Education
This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this programme.
conference-update Conference update
Oncology 
ER+ metastatic breast cancer: Highlights from the 13th APBCS Satellite Symposium

Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer  

Experts
Prof. Shaheenah Dawood, Prof. Heather McArthur, Prof. Javier Cortés, Prof. Frédérique Penault-Llorca
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2025
COR2ED
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Σειρά podcast για τη διαχείριση της θρόμβωσης

Αναλύσεις από καταξιωμένους ειδικούς ιατρούς. Πλοηγηθείτε στις καρτέλες για να επιλέξετε ένα επεισόδιο podcast

Experts
Prof. Dimitrios Tsakiris, Prof. Michael Nagler, Dr Lars Asmis, Prof. Jerzy Windyga
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Feb 2025
COR2ED Non-accredited Independent Medical Education
This educational programme is supported by an Independent Educational Grant from Viatris.
podcast Podcast
Oncology Obstetrics and Gynecology 
Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions

Understanding the role of molecular subtypes in guiding treatment selection

Experts
Prof. Xavier Matias-Guiu, Dr Jurjees Hasan
Endorsed by
Biomarker Collaborative ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 11 MIN
  • calendar Feb 2025
OBSTETRICS & GYNECOLOGY CONNECT  PRECISION ONCOLOGY CONNECT Non-accredited Independent Medical Education
This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this Video Podcast.
Explore all programmes